Shionogi $4507.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-32
RECRUITING6
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO67%
Delay Index: of 6 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +13.5 months). See all sponsors →
Open Shionogi on the live radar map → 📅 $4507.T readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| S-337395 NCT07214571 |
P2 | Recruiting | Respiratory Syncytial Virus Infections | 192 | 2026-12-30 |
| Sivopixant NCT06776432 |
P2 | Active, not recruiting | Sleep Apnea | 60 | 2026-12-31 (+13 mo) |
| Secutrelvir NCT07746544 |
P3 | Recruiting | COVID-19 | 1200 | 2027-07-31 |
| S-606001 NCT07123155 |
P2 | Recruiting | Pompe Disease | 45 | 2027-08-08 |
| BPN14770 NCT06717438 |
P2 | Active, not recruiting | Jordan's Syndrome; PPP2R5D Neurodevelopmental Disorder | 30 | 2027-12-31 (+21 mo) |
| aCCeleR8-001 NCT05101070 |
P1/2 | Recruiting | Solid Tumors | 282 | 2028-05-31 (+14 mo) |
| Naldemedine NCT05588323 |
P1/2 | Recruiting | Opioid-Induced Constipation (OIC) | 24 | 2028-06-15 (+46 mo) |
| Secutrelvir NCT07743580 |
P3 | Recruiting | SARS-CoV-2 | 2000 | 2028-06-30 |
| S-606001 NCT07750990 |
P2 | Not yet recruiting | Pompe Disease | 60 | 2028-08-31 |